Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model
Authors:
- Jinchao HouJHJinchao Hou
- Yun ChenYCYun Chen
- Zhangying CaiZCZhangying Cai
- Gyu Seong HeoGHGyu Seong Heo
- Carla M. YuedeCYCarla M. Yuede
- Zuoxu WangZWZuoxu Wang
- Kent LinKLKent Lin
- Fareeha SaadiFSFareeha Saadi
- Tihana TrsanTTTihana Trsan
- Aivi T. NguyenANAivi T. Nguyen
- Eleni ConstantopoulosECEleni Constantopoulos
- Rachel A. LarsenRLRachel A. Larsen
- 3 April 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (741) , eadj9052
Abstract
Microglia help limit the progression of Alzheimer’s disease (AD) by constraining amyloid-β (Aβ) pathology, effected through a balance of activating and inhibitory intracellular signals delivered by distinct cell surface receptors. Human leukocyte Ig-like receptor B4 (LILRB4) is an inhibitory receptor of the immunoglobulin (Ig) superfamily that is expressed on myeloid cells and recognizes apolipoprotein E (ApoE) among other ligands. Here, we find that LILRB4 is highly expressed in the microglia of patients with AD. Using mice that accumulate Aβ and carry a transgene encompassing a portion of the LILR region that includes LILRB4 , we corroborated abundant LILRB4 expression in microglia wrapping around Aβ plaques. Systemic treatment of these mice with an anti-human LILRB4 monoclonal antibody (mAb) reduced Aβ load, mitigated some Aβ-related behavioral abnormalities, enhanced microglia activity, and attenuated expression of interferon-induced genes. In vitro binding experiments established that human LILRB4 binds both human and mouse ApoE and that anti-human LILRB4 mAb blocks such interaction. In silico modeling, biochemical, and mutagenesis analyses identified a loop between the two extracellular Ig domains of LILRB4 required for interaction with mouse ApoE and further indicated that anti-LILRB4 mAb may block LILRB4-mApoE by directly binding this loop. Thus, targeting LILRB4 may be a potential therapeutic avenue for AD.Keywords
This publication has 66 references indexed in Scilit:
- APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spreadCell, 2023
- Hallmarks of neurodegenerative diseasesCell, 2023
- Plasmodium falciparum RIFIN is a novel ligand for inhibitory immune receptor LILRB2Biochemical and Biophysical Research Communications, 2021
- The Major Risk Factors for Alzheimer’s Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ PlaquesCell Reports, 2019
- A Unique Microglia Type Associated with Restricting Development of Alzheimer’s DiseaseCell, 2017
- Presynaptic dystrophic neurites surrounding amyloid plaques are sites of microtubule disruption, BACE1 elevation, and increased Aβ generation in Alzheimer’s diseaseActa Neuropathologica, 2016
- TREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease ModelCell, 2015
- Preparing Synthetic Aβ in Different Aggregation States2010
- Genome-wide Association Analysis Reveals Putative Alzheimer's Disease Susceptibility Loci in Addition to APOEThe American Journal of Human Genetics, 2008
- A novel regulatory role of gp49B on dendritic cells in T‐cell primingEuropean Journal of Immunology, 2008